Sign inJoin waitlistJoin the waitlist

PL

Peter Ljubenkov

Physician · University of California (San Francisco) School of Medicine

Credentials: · · ·

History

University of California (San Francisco) School of Medicine
2021–Present

Neurology
University of California (San Diego) Medical Center
2011–2015
Temple University School of Medicine
2007–2011

Research

Temporal order of clinical and biomarker changes in familial frontotemporal dementia
Nature Medicine · 2022 · 125 citations
Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration
Neurology · 2022 · 112 citations
Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A…
JAMA Neurology · 2020 · 100 citations

AB
Adam Boxer
42 papers
Julio Rojas-Martinez
28 papers
Bruce Miller
27 papers
AS
Adam Staffaroni
26 papers
Bradley Boeve
25 papers
Lawren VandeVrede
24 papers
HR
Howie Rosen
23 papers
JK
Joel Kramer
19 papers
Bradford Dickerson
18 papers
Irene Litvan
18 papers
AP
Alexander Pantelyat
15 papers
EH
Edward Huey
15 papers

Grants

Veri-T: A Phase 1 Placebo-Controlled Trial of Verdiperstat in Semantic Variant Primary Progressive Aphasia Due to Underlying FTLD-TDP
National Institute on Aging · R01
Contact PI · $3.3M · University of California, San Francisco
2021–2027

Clinical trials

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
Principal investigator · Active not recruiting · Phase 1
Peter Ljubenkov, MD
2022–2027
Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
Principal investigator · Unknown · Phase 2
Woolsey Pharmaceuticals
2021–2023
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Principal investigator · Completed · Phase 2
Alector Inc.
2019–2024
Alzheimer's Tau Platform: Master Protocol
Site PI · Recruiting · Phase 2
Paul S. Aisen
2026–2028